# A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.

> **NCT07164534** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Tata Memorial Hospital** · enrollment: 316 (estimated)

## Conditions studied

- Uterine Cervical Neoplasm

## Interventions

- **DIETARY_SUPPLEMENT:** Sodium-copper-chlorophyllin, a semi-synthetic derivative of chlorophyll, is made up of a mixture of sodium copper salts.

## Key facts

- **NCT ID:** NCT07164534
- **Lead sponsor:** Tata Memorial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2030-03
- **Final completion:** 2030-09
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07164534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07164534, "A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07164534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*